United StatesOwnership & classification
Founded: 2015
Ownership
STAT (also STAT News) is a US health, medicine and life-sciences news site launched on 4 November 2015 by John W. Henry, owner of The Boston Globe. It is produced by Boston Globe Media Partners and run as a separate brand. Ownership traces to John Henry, the billionaire businessman who bought the Globe in 2013.
Funding
Initially free, STAT has since built a paywalled subscription business (STAT+) alongside advertising, sponsored events and conferences, financed within the privately held Boston Globe Media group. It is a commercial, for-profit operation.
Affiliation & stance
STAT has no party, state or church ties and operates as an independent commercial newsroom focused on health and biotech, owned privately by John Henry's Boston Globe Media. Because it is privately and commercially owned with no party or government control, it is classified INDEPENDENT (matching the site's existing guess).
Editorial lean
- Our estimate
- Center
- Measured from coverage
- Centerbased on 201
74/100
Factual
71/100
Objective
237
Articles
237
reports
Factual: How accurately its articles report the facts, judged against primary sources and the cross-outlet consensus. Only articles that cite their sources are counted.
Objective: How neutral the writing is — whether reporting keeps the writer’s own preferences and opinions out of the article.
Recent coverage
Trump promises $100 checks for 20 million seniors for Medicare
President Trump announced that his administration will send approximately $100 to over 20 million senior citizens to assist with Medicare Part B premiums. The payments, described as 'checks,' will come from the Medicare Improvement Fund, which Trump referred to as a 'Slush Fund.' Eligible seniors will receive either a direct deposit of $90 or paper checks starting in early October. While the payment is intended to reduce monthly premiums, it will cover less than half of the standard $202.90 Part B premium. This move comes amid Trump's efforts to improve economic sentiment ahead of the midterms, following other financial promises such as potential $5,000 payments for adults if Republicans win the election and $500 Obamacare rebate proposals. Critics note that many of these promises lack concrete implementation plans.
STAT+: Judges skewer HHS arguments in hearing over Medicare Advantage audits lawsuit
Federal appeals court judges expressed strong disapproval of the Trump administration's arguments during a hearing regarding Humana's lawsuit against the Health and Human Services Department (HHS). The case, Humana v. Kennedy, challenges HHS' final rule for auditing Medicare Advantage plans, which Humana claims deviates significantly from a previously proposed rule and fails to provide adequate notice and opportunity for stakeholder input. In September 2025, a federal judge invalidated the rule, known as the Risk Adjustment Data Validation (RADV) rule. HHS appealed this decision in November 2025, but during Monday's oral arguments before a three-judge panel of the U.S. Court of Appeals for the Fifth Circuit, the judges appeared inclined to overturn the rule once again. The case highlights ongoing legal battles over regulatory changes impacting Medicare Advantage plans.
New Trump Transparency Rules For Health Insurance: How You Could Benefit
The Trump administration has finalized new healthcare price transparency regulations aimed at helping Americans better understand the costs of medical treatments before receiving them. The rules, introduced by the Centers for Medicare & Medicaid Services (CMS), require health insurers and employer-sponsored plans to provide more standardized pricing information and expand access to expected out-of-pocket expenses. This is intended to allow patients to compare prices and avoid unexpected costs. HHS Secretary Robert F. Kennedy emphasized the importance of giving patients clear and reliable information to make informed decisions. The regulations build upon previous transparency initiatives under the Trump administration, which reportedly led to a reduction in the prices of some of the most expensive healthcare services. While supporters argue that greater transparency will drive competition and reduce costs, critics suggest that the increased complexity of the information might overwhelm average consumers.
STAT+: Nobel-winning optogenetics research has led to experimental treatments for blindness and Alzheimer’s
The article discusses the groundbreaking research in optogenetics, a field pioneered by Karl Deisseroth, which has led to experimental treatments for conditions like blindness and Alzheimer’s. Deisseroth, along with German researchers Peter Hegemann and Georg Nagel, was awarded the 2026 Nobel Prize for Medicine for their development of tools that allow precise manipulation of neural activity. The technology enables targeting of specific cells within the brain, offering potential breakthroughs in understanding and treating neurological disorders. While the article highlights the scientific achievements and implications of the research, it does not delve into controversies or differing viewpoints surrounding the technology.
STAT+: Prices, prices, prices
The article discusses the rising cost of health insurance premiums in the United States, which are forcing both workers and employers to reevaluate their approach to providing coverage. These high premiums are attributed to the healthcare industry's elevated and opaque pricing structures. The piece highlights the financial burden these costs impose and suggests that this issue is prompting significant changes in how health care is accessed and funded. The author invites reader input on the topic, indicating a focus on exploring various perspectives on the issue.
STAT+: Utah plows ahead with more health AI pilots for prescriptions, women’s health
Utah regulators have approved a pilot program allowing an AI-driven healthcare startup, Nolla Health, to evaluate patients and recommend drug prescriptions for mild-to-moderate acne treatment. The AI system will analyze patient data and skin images to suggest low-risk medications, with initial oversight by licensed clinicians. Nolla plans to eventually remove the human review requirement, marking a step toward broader AI integration in prescription practices. This initiative is part of Utah's 'AI sandbox' program, which provides regulatory flexibility for testing AI technologies under state supervision. The move reflects growing interest in leveraging AI for personalized medical care while raising questions about safety, accountability, and ethical implications.
STAT+: Lilly’s Jaypirca approved as first-line CLL therapy
The article mentions the approval of Lilly’s Jaypirca as a first-line therapy for chronic lymphocytic leukemia (CLL), but does not provide detailed information about the drug, its approval process, or its implications for treatment. The piece appears to be part of a promotional or subscription-based content section, featuring a personal anecdote involving a child named Silas Mirza-Ladd. It references broader issues such as stem cell research controversies and drug pricing challenges, suggesting these topics are relevant to the publication's focus areas. However, the main content related to Jaypirca is either truncated or linked to a premium section requiring subscription access.
STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
The article begins with a lighthearted greeting and references the return of routine work life. It then shifts focus to pharmaceutical developments, highlighting Vaxcyte's pneumococcal vaccine, VAX-31, which showed positive results in a Phase 3 trial against competitors Pfizer and Merck. The vaccine targets 31 strains of bacteria, surpassing the coverage of existing vaccines. The company still needs additional trials for regulatory approval. Separately, the FDA has delayed reviewing a hemophilia A drug from Novo Nordisk due to manufacturing facility issues, though safety and effectiveness data remain unaffected. The article concludes by directing readers to STAT+ for further details.
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
Vaxcyte, a California-based biotechnology company, announced that its experimental pneumococcal vaccine, VAX-31, has successfully met the primary endpoints in a Phase 3 clinical trial. This development positions Vaxcyte to enter the competitive market for pneumococcal vaccines, which are used to prevent diseases such as pneumonia caused by various bacterial strains. The trial involved more than 3,500 adults aged 50 and older who were randomly assigned to receive either VAX-31, Pfizer’s Prevnar, or Merck’s Capvaxive. Researchers evaluated the participants' antibody responses to different strains of the bacteria. VAX-31 is designed to provide protection against 31 serotypes, surpassing the coverage offered by Pfizer’s and Merck’s vaccines, which cover 20 and 21 strains respectively.
Could we one day vaccinate against every cancer?
The article begins with a promotional message for STAT News' Morning Rounds newsletter, encouraging subscribers to sign up. It then mentions the announcement of the Nobel Prize for Medicine winners and invites readers to share their opinions on whether they won their office pool or believe another research team was unfairly overlooked. The content does not provide detailed information about the Nobel Prize winners, their work, or any specific scientific breakthroughs related to cancer vaccines.
Hospital and pharmaceutical prices are smothering America’s businesses
The article discusses the rising costs of healthcare in the United States, particularly focusing on how hospital and pharmaceutical prices are contributing to increased health insurance premiums for both employees and employers. It highlights that these high prices are a major driver of overall healthcare spending, making it difficult for individuals and businesses to manage their costs. Gerard Anderson, a professor at Johns Hopkins University and former contributor to Medicare's hospital payment system, emphasizes that the issue lies primarily in the uncontrolled pricing within the healthcare industry. His research over several decades consistently points to price inflation as the main cause of America's unusually high healthcare expenditures.
STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
A late-stage mRNA cancer vaccine showed promise in preventing the recurrence of melanoma, raising hopes for its potential application against other cancers. Merck and Moderna reported in August that combining their mRNA vaccine with existing treatments delayed melanoma progression. Researchers and industry leaders expressed cautious optimism about the implications for cancer immunotherapy, noting the potential for broader applications. However, the results also highlight ongoing challenges in determining which cancers could benefit most from this approach and whether mRNA technology can consistently deliver effective outcomes.
STAT+: Are stem cells the next peptides? These advocates think RFK Jr. could make it happen
Chuck Meeker, a stem cell entrepreneur, expressed optimism about the potential for FDA engagement with the stem cell industry, drawing parallels between stem cells and peptides in regenerative medicine. At the PepMed 2026 conference, Meeker suggested that the FDA's growing interest in peptides might open doors for stem cells, which remain largely unregulated. While the FDA did not confirm upcoming actions, industry advocates see this as an opportunity to transition stem cell therapies from the gray market to approved treatments. The article highlights the intersection of regulatory developments and commercial interests within regenerative medicine.